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Stim1
Orai1
TRPC1Endothelial progenitor cells (EPCs) may be recruited from bone marrow to sustain the metastatic switch in a
number of solid cancers, including breast cancer (BC) and renal cellular carcinoma (RCC). Preventing EPC mobi-
lization causes tumor shrinkage. Novel anti-angiogenic treatments have been introduced in therapy to inhibit
VEGFR-2 signaling; unfortunately, these drugs blocked tumor angiogenesis in pre-clinicalmurinemodels, but re-
sulted far less effective in human patients. Understanding the molecular mechanisms driving EPC proliferation
and tubulogenesis in cancer patients could outline novel targets for alternative anti-angiogenic treatments.
Store-operated Ca2+ entry (SOCE) regulates the growth of human EPCs, and it is mediated by the interaction be-
tween the endoplasmic reticulum Ca2+-sensor, Stim1, and the plasmalemmal Ca2+ channels, Orai1 and TRPC1.
EPCs do not belong to the neoplastic clone: thus, unlike tumor endothelium and neoplastic cells, they should not
remodel their Ca2+ toolkit in response to tumor microenvironment. However, our recent work demonstrated
that EPCs isolated from naïve RCC patients (RCC-EPCs) undergo a dramatic remodeling of their Ca2+ toolkit by
displaying a remarkable drop in the endoplasmic reticulum Ca2+ content, by down-regulating the expression
of inositol-1,4,5-receptors (InsP3Rs), and by up-regulating Stim1, Orai1 and TRPC1. Moreover, EPCs are dramat-
ically less sensitive to VEGF stimulation both in terms of Ca2+ signaling and of gene expression when isolated
from tumor patients. Conversely, the pharmacological abolition of SOCE suppresses proliferation in these cells.
These results question the suitability of VEGFR-2 as a therapeutically relevant target for anti-angiogenic treat-
ments and hint at Orai1 and TRPC1 as more promising alternatives. This article is part of a Special Issue entitled:
13th European Symposium on Calcium.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
A ﬁnely tuned increase in intracellular Ca2+ concentration ([Ca2+]i)
is the ubiquitousmechanismwhereby the organism regulates functions
as diverse as fertilization, embryonic development, muscle contraction,
immune response, learning and memory [1–3]. The indispensable role
that calcium signaling has assumed in virtually all life forms across the
phylogenetic tree depends of the unmatched versatility of this intracel-
lular messenger as compared to other signaling pathways [1,2]. The
spatio-temporal proﬁle as well as the amplitude and duration of intra-
cellular Ca2+ elevationsmay beprecisely tailored to target a speciﬁc cel-
lular function among the multitude of those endowed with Ca2+-
sensitivity, such as proliferation, gene expression, protein folding and
processing, motility, nitric oxide (NO) and hydrogen sulphide (H2S)opean Symposium on Calcium.
39 382 987527.
.synthesis, cytoskeleton remodeling, exocytosis, energy production, pro-
grammed cell death or necrosis [1,2,4,5]. It is, therefore, not surprising
that any alteration in the delicate balance between the mechanisms
feeding Ca2+ into the cytoplasm and those terminating the signal to
prevent the cytotoxic consequences of a prolonged [Ca2+]i increase,
will perturb cellular homeostasis. It has now been accepted that de-
rangement of the Ca2+ machinery is central to the onset of many life-
threatening diseases, such as heart failure, neurodegenerative diseases
and cancer [6–9]. In particular, the aberrant expression of speciﬁc
Ca2+ channels and transporters, as well as their altered activity, may
contribute to establish some of the ten deﬁned cancer hallmarks
[8–10], including limitless replicative potential, insensitivity to apopto-
sis, tissue invasion andmetastasis, and angiogenesis, i.e. the sprouting of
new capillary branches from adjacent blood vessels. The development
of tumor vasculature, however, may impinge on alternative mecha-
nisms, that will bementioned in the next paragraph and include the re-
cruitment of circulating endothelial progenitor cells (EPCs).While it has
long been known that growth factors utilize Ca2+ signals to activate
1959F. Moccia, V. Poletto / Biochimica et Biophysica Acta 1853 (2015) 1958–1973mature endothelial cells [11,12], vascular endothelial growth factor
(VEGF) stimulates their immature progenitors through an oscillatory
increase in [Ca2+]i, as demonstrated by a recent series of studies from
our group [13–15]. In the present article, we will discuss how the
Ca2+ toolkit is deranged in EPCs derived from cancer patients, thereby
leading to the suppression of the pro-angiogenic Ca2+ response to
VEGF. This feature might explain the well known failure of anti-VEGF
drugs to cause a persistent inhibition of tumor growth andmetastatiza-
tion in cancer patients. The concomitant up-regulation of Stim1, Orai1
and Canonical Transient Receptor Potential channel 1 (TRPC1), that con-
trol proliferation and in vitro tubulogenesis both in normal EPCs and in
their malignant counterparts, hints at store-operated Ca2+ entry
(SOCE) as a promising target to devise alternative therapies to treat
highly angiogenic tumors, such as renal cellular carcinoma (RCC) and
breast cancer.
2. Mechanisms of tumor vascularization and resistance to anti-
angiogenic therapy
The development of new blood vessels is an essential step for tumor
progression, invasion and dissemination (metastatization) to distant or-
gans, where the primary neoplasm gives rise to secondary lesions. The
pioneering work conducted by Judah Folkman provided the ﬁrst evi-
dence that tumors cannot enlarge beyond the physical constraints im-
posed by nutrient diffusion rates, i.e. 1–2 mm3, without having access
to peripheral circulation. The formation of a patent vasculature is indis-
pensable for cancer cells to obtain the necessary oxygen and nutrient
supplies and to clear out their metabolic waste. Moreover, the “angio-
genic switch”, the mechanismwhereby a dormant hyperplasia is turned
into a highly vascularized tumor, paves the way for cancer cell to escape
from the primary lesion site and disseminate towards neighboring or
even distant sites [16,17]. Disseminated tumor cells may in turn develop
the secondary macrometastases that ultimately lead to patient death
[18]. The capability of cancer cells to intravasate into peripheral circula-
tion and disseminate to remote organs is exacerbated by the well
known chaotic disorganization of tumor vessels. These are featured by
a number of morphological, cellular, and molecular abnormalities that
all together concur to shape a dilated, tortuous, and hyperpermeable
microvascular network inside the neoplasm [19,20]. The remarkable het-
erogeneity in tumor endothelium is dictated by threemainmechanisms,
which are not mutually exclusive, but may interact to produce aberrant
endothelial cells: 1) the cross-talk with the surrounding microenviron-
ment— featured by hypoxia, lowpH, disorganized basementmembrane,
elevated interstitial ﬂuid pressure, enrichment in growth factors and cy-
tokines —which may impart both genetic and epigenetic modiﬁcations
to tumor endothelial cells (TECs); 2) the vascular bed of origin, which
conveys a site-speciﬁc epigenetic footprint to endothelial cells sprouting
towards the neoplastic lesion; and 3) the contribution of additional
mechanisms to tumor vascularization, including vasculogenic mimicry,
intussusceptive angiogenesis, vessel co-option, recruitment and engraft-
ment of hematopoietic and endothelial progenitor cells [19,21]. Relevant
to the aims of the present article, a growing number of studies have now
established that the concerted interaction between local endothelial cells
and circulating EPCs drive the angiogenic switch during tumor growth
and metastatic progression [20,22,23]. This discovery opened a new av-
enue in the investigation of deranged endothelial Ca2+ signals during
neoplastic transformation and proposed this intracellular pathway as a
molecular target for novel anti-angiogenic treatments [15,20,24–26].
2.1. Evidence for EPC contribution to tumor vascularization
The angiogenic switch is initiated by the increased expression and/
or activation of hypoxia-inducible factor-1α (HIF-1α), which is conse-
quent to the dramatic decrease in oxygen tension (PO2) occurring in
growing tumors. HIF-1α is, in turn, a transcription factor that induces
the transcription of genes encoding for several growth factors andcytokines, such as VEGF, epidermal growth factor (EGF), basic ﬁbroblast
growth factor (bFGF), insulin-like growth factor-2 (IGF2), and stromal
derived factor-1α (SDF-1α) [12,22,27]. These mediators are released
into circulation: 1) to stimulate adjacent capillaries to sprout towards
the avascular hyperplasia and 2) to stimulate the bone marrow niche
to switch from a quiescent state to a pro-tumorigenic environment
[15,20,22,27]. While tumor-associated angiogenesis has long been in-
vestigated, the contribution of both hematopoietic progenitor cells
(HPCs) and EPCs has only recently come of age [12,22,27]. Angiogenesis
is a complex andmultistepped process that is initiatedwhen local endo-
thelial cells are stimulated by VEGF to synthesize and secrete matrix
proteases (MMPs) for the breakdown of the membrane basement
surrounding the capillaries they belong to. As a consequence, endothe-
lial cells are detached from the vascular wall andmigrate into the extra-
cellular matrix, where they proliferate and assemble into patent tubes
that provide the expanding tumor with blood, nutrients, and oxygen.
The stabilization of the immature vessel requires the attraction of acces-
sory cells, such asmural cells and pericytes, which contribute to the for-
mation of a new basement membrane and a ﬁrm extracellular matrix
[17]. In addition to sprouting angiogenesis, tumor vascularization is fa-
cilitated by the engagement of bone marrow-derived HPCs, including
Tie2-expressing monocytes, F4/80+ CD11b+ tumor-associated macro-
phages (TAMs), CXCR4+ VEGFR1+ hemangiocytes, GR1+ CD11b+ “my-
eloid-derived suppressor cells” (MDSCs), CD45+/CD11b+myeloid cells,
and inﬁltrating neutrophils and mast cells [22,28]. These cells may ei-
ther adopt an endothelial phenotype, thereby directly lining tumor ves-
sels, or exert perivascular functions by emitting paracrine signals, such
as growth factors and cytokines [22,28]. Nevertheless, the precise bio-
logical role of bone marrow-derived HPCs in neovessel formation re-
mains to be elucidated. Conversely, the contribution of circulating
EPCs to the angiogenic switch has now been widely accepted [15,20,
22,23,29,30]. EPCs are mobilized from both bone marrow and vascular
wall stem cell niches by tumor cells-derived VEGF and SDF-1α: once
these mediators are released into circulation, they establish a concen-
tration gradient that paves the way for EPC recruitment both to the pri-
mary tumor lesion and to the more distant pre-metastatic niches.
Herein, EPCsmay both emanate angiogenic factors to stimulate local an-
giogenesis and physically engraft within tumor vasculature, thereby in-
ducing the transition from a dormant undetectable lesion to a deadly
metastatic cancer [15,20,22,28]. A number of studies hint at the vital
role served by circulating EPCs in supporting tumor growth and meta-
statization. First, the transplantation of bone marrow-derived cells ex-
pressing the β-galactosidase gene (lacZ) under the control of an
endothelial-speciﬁc promoter recapitulated angiogenesis in a xenograft
model of B6RV2 lymphoma. The subsequent histological examination
revealed lacZ staining throughout tumor vasculature, thereby suggest-
ing that bone marrow sustains the angiogenic switch [31]. Second, sex
chromosome ﬂuorescence in situ hybridization (FISH) analysis of sec-
ondary malignancies in patients who were previously transplanted
with HPCs from a sex-mismatched donor disclosed the presence of
bone marrow-derived cells in the associated vessels [30]. Third, the
physical engraftment of bone marrow-derived GFP+ EPCs into tumor-
associated bed has been demonstrated by assessing luminal cells posi-
tive for the following markers in three transplanted tumors (B6RV2
lymphoma, Lewis lung carcinoma or LLC, and melanoma) and one
transgenic breast cancer mouse model (MMTV-PyMT): 1) GFP, which
indicates bone marrow origin; 2) isolectin IB4, which conﬁrms luminal
integration; 3) CD31, which is a typical endothelial antigen; and
4) CD11b, which rules out any hematopoietic contamination [22,23,
32]. Fourth, EPCs transducedwith a construct encoding for GFP inserted
under the control of the transcription factor inhibitor of DNA binding 1
(Id1), which is selective for EPCs, promoter, have been tracked during
their path from the bonemarrow towards tumor vasculature in a xeno-
graftmodel of LLC [33]. Fifth, the conditional suppression of Id1, a helix–
loop–helix transcriptional repressor that drives EPC egression from
bone marrow, did not affect tumor onset in mice transplanted with
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tient death [32]. Similarly, selective elimination of Dicer, which leads to
the suppression of MiR-10b and MiR-196b, has recently been shown to
impair EPC-mediated vascularization of LLC [34]. Table 1 summarizes all
the evidences in favor of EPC contribution to tumor growth. Consistent
with the role they play in cancer neovascularization, the higher frequen-
cy of circulating EPCs correlates with enhanced angiogenesis and tumor
volume and is associated with decrease rate of patient survival [20,22,
28]. It should, however, be pointed out that the extent of EPC incorpora-
tion within tumor vasculature is extremely variable, ranging from 0% to
more than 90% (Table 1) [22,23,32,34]. This heterogeneitymay be easily
accounted for a number of intersecting factors that will be discussed in
the next paragraph.
2.2. The controversy about EPC contribution to tumor vasculature: hemato-
poietic vs. non-hematopoietic EPCs
The controversy about EPC involvement in malignant transforma-
tion has been engendered by the wide variety in the methods of tissue
collection, in the number of cells injected and in the animal models in-
vestigated to examine the composition of cancer vessels [22]. InTable 1
Summary of the evidences in favor or against EPC contribution to tumor vascularization.
Tumor type Tumor stage % of contribution BM tracking
Colon cancer (MCA38) s.c. 1–3 weeks Positive Flk-lacZ or T
Lymphoma cell (B6RV2) s.c. 2 weeks 90% Rosa26-LacZ
Neuroblastoma cell (NXS2) s.c. ND 5% BM cells exp
IGFP
Lewis lung carcinoma (LLC) s.c. 2 weeks 35% Human β2-m
LLC, s.c., Melanoma (B16) s.c. Late stage Negative Tie2-GFP
Fibrosarcomas (MCA/129) s.c. 2 weeks 50% Rosa26-LacZ
Pten+/−mouse (uterine carcinoma and
lymph hyperplasia)
Spontaneous 16% — uterine
carcinoma
Negative —
lymph
hyperplasia
Rosa26-LacZ
MMTV-PyMT mouse 10–
12 weeks
1.3% Rosa26-LacZ
B16F1 s.c. 2–3 weeks Negative Actb-GFP
LLC s.c., B6RV2 s.c. 2 weeks Negative Endothelial-
R26REYFP
RIP1-Tag5 mice AlbTag 10–
16 weeks
3–38% Tie2Cre × RA
Various human tumors ND 1–12% X or Y chrom
LLC s.c., B16 s.c., Breast cancer cell
(MCa8) orth.
ND b1% Actb-GFP, Ti
LLC s.c., B16F0 (ortho); MMTV-PYMT
mouse
2 weeks 2–20% Actb-GFP
LLC s.c., MMTV-PYMT mouse Lung
metastasis
12% Actb-GFP
B16 s.c. 2–3 weeks Negative Actb-GFP, VE
Dorsal skinfold chamber model xenograft
of rat C6 cells (glioblastoma) c.a.
1–2 days Positive DiI-labeled E
LLC s.c. 5 days
2 weeks
Positive
Positive
DiI-labeled C
GFP+ bone m
Human U87 glioma, ﬂanks 28 weeks
Palpable
tumor
Positive
Positive
CFU-ECs
Carboxyﬂuor
succinimidyl
Abbreviations: c.a.: carotid artery; DKK1: Dickkopf 1; FACS: ﬂuorescent activated cell sorting; I
receptor for advanced glycated end products; s.c.: subcutaneous injection.addition, EPC-mediated neovascularization depends on type, stage and
location of the tumor. This feature has been unveiled by utilizing mice
heterozygous for the tumor suppressor Pten (Pten+/−), thatmay exhib-
it different malignant neoplasms, including uterine carcinomas and
lymph hyperplasia. EPC-induced angiogenesis was found in the former,
while it was undetectable in the latter [35]. A series of studies from the
same group revealed that EPCs home to implanted LLC, B6RV2 lympho-
ma and melanoma and to spontaneous breast cancer occurring in
MMTV-PyMTmice and in developingpulmonarymetastases before ves-
sel formation [23,32]. As a consequence, they are diluted both by local
endothelial cells and bone marrow-derived hematopoietic cells, a fea-
ture that might underestimate their contribution at later stage of
tumor progression [22,28]. Finally, and perhaps the most important
source of variability in the evaluation of their involvement in the angio-
genic switch, EPC phenotype is far from being clearly identiﬁed (Fig. 1
and Table 2) [36,37]. The term EPC cannot be referred to a unique cell
population featured by speciﬁc surface markers thatmake it easy to de-
tect and quantify in vivo, but encompasses at least two separate subsets
that may be classiﬁed as hematopoietic and non-hematopoietic [37].
The confusion in EPC deﬁnition has been engendered by: 1) the ability
of hematopoietic progenitor and stem cells to sustain vessel growthEndothelial cell
marker
BM-EC detection
ie2-LacZ IHC Asahara et al.
[181]
vWF IHC Lyden et al.
[31]
ressing MSCV-tsFlk-1- CD31and CD34 IF Davidoff
et al. [182]
icroglobulin CD31 and vWF IF Reyes et al.
[183]
CD31 IF, 3D microscopy De Palma
et al. [184]
vWF IHC Garcia-Barros
et al. [185]
CD31 IHC Ruzinova
et al. [35]
CD31 IHC Dwenger
et al. [186]
CD31 and vWF IHC Rajantie et al.
[187]
SCL-Cre-ER × R26R or CD31 IF Goethert
et al. [188]
GE-EGFP Lectin staining,
CD31
IHC, FACS Spring et al.
[189]
osomes vWF FISH Peters et al.
[30]
e2-GFP CD31 IF, FACS Duda et al.
[190]
CD31, VE-
cadherin, Lectin
staining
FACS, 3d microscopy Nolan et al.
[23]
CD31 IF, FACS Gao et al.
[32]
GFR2-LacZ CD31, vWF IF Purhonen
et al. [191]
CFCs DiI staining Intra-vital
multiﬂuorescence
microscopy
Bieback et al.
[40]
FU-ECs
arrow-derived cells
CD31, DiI staining
CD31
IHC
IHC
Jung et al.
[192]
escein diacetate
ester-labeled CFU-ECs
CD31
DiI staining
IHC
IHC
Zhang et al.
[193]
F: immunoﬂuorescence; IHC: immunohistochemistry; ortho: orthotropic injection; RAGE:
Fig. 1. Isolation and identiﬁcation of distinct endothelial progenitor cell subtypes. This ﬁgure depicts themost commonprotocols currently employed to isolate EPCs from either peripheral
and umbilical cord blood. CFU-ECs (colony forming unit-endothelial cells) require a 5–9 day process which starts with the seeding of 5 × 106 mononuclear cells (MNCs) on ﬁbronectin-
coated dishes in a commercially available medium enriched with 20% fetal bovine serum (FBS) and VEGF. Non-adherent cells are removed after 24 h and replated on new ﬁbronectin-
coated dished for further 5–9 days before giving raise to a visible EPC colony. Circulating angiogenic cells (CACs) are obtained from the adherent fraction of MNCs after 4 days of culture
in endothelial conditions and do not display any signiﬁcant colony forming ability. The culture of endothelial colony forming cells (ECFCs) requires the seeding of MNCs onto collagen-
coated culture dishes in a commercially available endothelial growthmedium (EGM-2, Lonza) for 48 h. At this time, non-adherent cells are discarded and ECFC-derived colonies with cob-
blestone morphology appear after 10–20 days when MNCs are harvested from peripheral blood. For each EPC subgroup, the panel of antigens for which they are positive (+), partially
positive (+/−), or negative has been added on the right. The centrifuge tube on the left side contains the fraction of mononuclear cells from which each EPC subtype is derived.
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lack of a combination of markers and receptors selective for truly endo-
thelial EPCs [15,36,38]. The hematopoietic EPCs comprise both colony
forming unit-endothelial cells (CFU-ECs) and circulating angiogenic
cells (CACs), while the non-hematopoietic EPCs consist of the so-
called endothelial colony forming cells (ECFCs) (Fig. 1) [15,36,37].
CFU-ECs and CACs may be recruited towards the growing tumor, but
they do not directly incorporate within neovessels: these cells display
a peri-vascular location and support malignant growth in a paracrine
manner (Fig. 2). Conversely, ECFCs possess an impressive clonogenic
potential, are committed to differentiate into mature endothelial cells,
form capillary-like structures in vitro and patent vessels in vivo [15,36,
37]. Therefore, they are now regarded as bona ﬁde EPCs that may phys-
ically engraft within cancer vasculature (Fig. 2) [37]. Only an extensive
gene expression proﬁling combined with a rigorous ultrastructural ex-
amination and an array of functional assays permits to distinguish be-
tween CFU-ECs, CACs and ECFCs [37,39]. As illustrated above, only aTable 2
Functional properties of the three better characterized endothelial progenitor cell
populations.
CFU-ECs CACs ECFCs
Clonal proliferative potential − − +
Replating ability − − +
In vitro tube formation (Matrigel scaffold) +/− +/− +
Neovessel formation in vivo − − +
Homing to ischemic sites in vivo + + +
Homing to primary tumors in vivo + ND +
Paracrine stimulation of angiogenesis + + +
Abbreviations: CFU-ECs: colony forming unit-endothelial cells; CACs: circulating angio-
genic cells; ECFCs: endothelial colony forming cells.few groups have established the integration of bone marrow-derived
cells endowed with endothelial markers, but lacking hematopoietic an-
tigens, into tumor vasculature [23,32–35]. However, recent studies have
conﬁrmed that human ECFCs, which truly belong to the endothelial lin-
eage, may be recruited to sites of tumor angiogenesis upon their direct
injection into the bloodstream of several murine models of human ma-
lignancies. More speciﬁcally, DiI-labeled ECFCs actively home to subcu-
taneously implanted glioma [40] and breast cancer [41] xenografts as
well as to LLC metastases [42]. It turns out that ECFC represents the
most suitable subset to investigate the molecular mechanisms driving
EPC incorporation into tumor vasculature and, consequently, to identify
the most effective target(s) to adverse metastatic progression.2.3. Is VEGFR-2 the most suitable target for anti-angiogenic treatments?
VEGF has long been known to stimulate angiogenesis and promote
endothelial growth/survival by the activation of its cognate receptor,
VEGFR-2 (also termed KDR in humans or Flk-1 in mice), which pos-
sesses an intrinsic and druggable tyrosine kinase activity [43]. There-
fore, the inhibition of VEGF signaling by either humanized monoclonal
anti-VEGF antibodies (Bevacizumab [Avastin]) or multi-targeted pan-
VEGF receptor tyrosine kinase inhibitors (Sunitinib [Sutent], Pazopanib
[Votrient], Sorafenib [Nexavar], and Vandetanib [Zactima]), has been
approved by the US Food and Drug Administration and introduced in
clinical practice to treat a growing number of advanced metastatic can-
cers, such as renal cellular carcinoma (RCC), breast cancer, non-
squamous non-small cell lung cancer, colorectal cancer, and recurrent
glioblastoma, either in conjunction with chemotherapeutics or as
monotherapy [17,43]. In principle, this approach is further recommend-
ed by the notion that EPCs require a functional VEGFR-2 to proliferate,
engraftwithin nascent vessels, anddifferentiate intomature endothelial
Fig. 2. Themechanism of tumor vascularization by tumor endothelial progenitor cells. Cancer-released growth factors (such as VEGF) and cytokines (such as SDF-1α) stimulate EPC egres-
sion from bone marrow, thereby increasing their circulating levels and homing to growing tumor. Herein, ECFCs, which truly belong to the endothelial lineage and therefore non-hema-
topoietic, may either directly incorporate within tumor neovessels or stimulate local angiogenesis through the paracrine release of further growth factors. Conversely, CFU-ECs and CACs,
which derive from hematopoietic precursors, may only accelerate tumor growth and metastizazion in a paracrine-manner.
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models seemingly conﬁrmed the feasibility of targeting VEGFR-2 to
prevent EPC stimulation in cancer patients. EPC-mediated vasculariza-
tion and growth of either LLC or B6RV2 tumors were blocked by
inhibiting VEGFR-2 through the delivery of a neutralizing antibody
(DC101) [31] or of a speciﬁc short hairpin RNA (shRNA) [33]. Moreover,
the EPC spike in systemic circulation induced by chemotherapeutics
(paclitaxel, 5-FU, and docetaxel) and vascular disrupting agents
(VDAs; combretastin-A4 phosphate, OXi-4503, onbrabulin), that com-
promise the already established tumor vasculature without interfering
with bone marrow activation, was abolished by several drugs targeting
VEGFR-2, such as DC101 [44,45] and sunitinib [46]. Despite the initial
enthusiasm raised by pre-clinical studies conducted on established can-
cer models, oncological practice revealed all the unexpected limits of
anti-angiogenic medicine, which depend on our poor comprehension
of the intrinsic mechanisms of vascular growth [17,43]. Anti-VEGF in-
hibitors, such as bevacizumab, sorafenib and sunitinib, caused only a
modest increase in progression-free survival (PFS) of cancer patients,
while they did not signiﬁcantly improve their overall survival (OS), ei-
therwhen administrated aloneor in combinationwith standard chemo-
therapy and VDA [20,43,47]. This is why resistance shortly arises in the
majority of patients, while others are intrinsically refractory and do not
display any response to the treatment [17,20]. A number of explana-
tions have been offered to shed light on the therapeutic failure of
VEGF blockers and this issue has recently spurred an intense debate
[43,47]. The most important issue to bear in mind when analyzing the
scarce efﬁcacy of VEGF pathway inhibitors is the tremendous impact
that tumor microenvironment may exert on its own vasculature. First,
neoplastic transformation is accompanied by the HIF-1α-mediated re-
lease of alternative growth factors, includingbasicﬁbroblast growth fac-
tor (bFGF), epidermal growth factor (EGF), placental growth factor
(PlGF), and angiopoietin-1, whichmay replace VEGF in the cellular stro-
ma and render the inhibition of its cognate receptor ineffective [43,47].
Second, anti-angiogenic drugs have been developed on the basis of a
wrong rationale, i.e. that cancer endothelium maintains the same
features as non-transformed one, including low mutations rate, which
makes it genetically stable and less prone to acquire drug resistance.-
Unfortunately, it is now evident that TECs display morphological, cyto-
logical and functional differences as compared to normal endothelial
cells, including chromosomic aberrations, higher proliferative potential
and resistance to pro-apoptotic stimulation, and lower sensitivity to
cytotoxic drugs [21]. Third, different cancer types have long been
thought to require the same process, i.e. VEGF-mediated angiogenesis,to be vascularized. This notion is, however, false as intussusceptive an-
giogenesis and vasculogenic mimicry are utilized by melanoma and
gliobastoma to gain access to the host vascular system, while vessel
cooption is indispensable to nourish lung adenocarcinoma and cutane-
ous melanoma [48]. These alternative mechanisms of tumor vessel
growth do not necessarily require VEGF and are, therefore, insensitive
to classic anti-VEGF inhibitors [43,48]. EPC-mediated vascularization
may certainly be included among these alternative modes of tumor
expansion andmetastatization. Their earlymobilization frombonemar-
rowdoes not only sustain the angiogenic switch that promotesmetasta-
tic progression (see above); a delayed EPC burst is induced by cytotoxic
drugs and VDAs, thereby inducing the well known phenomenon of ac-
quired resistance that leads to patient death despite for continuous
treatment [49,50]. Most, if not all, the studies assessing the role of
VEGFR-2 in EPC proliferation and recruitment to tumor site, have been
conducted on mice xenografted with human cancers and injected
with EPCs obtained by normal, i.e. healthy, donors. As VEGF signaling
is functional in these cells [13,14,51–53], it is not surprising that
blocking VEGFR-2 prevents EPC activation and causes tumor shrinkage
in pre-clinical settings. Given the impact of tumor microenvironment
on resident endothelium, we endeavored to assess whether and how
the pro-angiogenic Ca2+ signaling toolkit is deranged in ECFCs harvest-
ed fromperipheral blood of naïve patients suffering fromRCC. The ratio-
nale behind our investigations was that only tumor EPCs could be
reliably employed to ascertain whether VEGFR-2 is a suitable target to
suppress EPC engagement in these patients. Moreover, distinct compo-
nents of the endothelial Ca2+ machinery can be selectively enlisted by
different growth factors to stimulate proliferation and tube formation
[11,25]; therefore, we reasoned that such investigation could introduce
novel signaling pathways, e.g. store-operated Ca2+ entry (SOCE) or
Transient Receptor Potential (TRP) channels, as alternative therapeutic
tools in anti-angiogenic therapy.
3. Ca2+ signaling in endothelial progenitor cells
An intricate network of signaling pathways is set in motion upon
VEGF binding to its cognate receptor, VEGFR-2, to stimulate endothelial
cell growth/survival and promote tumor vascularization in vivo.
The downstream mediators of VEGFR-2 include, but are not limited to:
1) phospholipase Cγ (PLCγ), which may either lead to an increase
in [Ca2+]i or engage the protein kinase C (PKC)/Ras/MEK/MAPK
cascade, 2) cytosolic PLA2, which is activated upon extracellular
signal-regulated kinase (ERK)-mediated phosphorylation and controls
1963F. Moccia, V. Poletto / Biochimica et Biophysica Acta 1853 (2015) 1958–1973PGI2 production; 3) phosphoinositide 3-kinase (PI3K), which in turn re-
cruit the protein kinase B (PKB)/Akt pathway via an increase in
phosphatidylinositol-3,4,5-trisphosphate (PIP3) to activate endothelial
nitric oxide (NO) synthase (eNOS) and inhibit B-cell lymphoma 2
(Bcl-2)-associated death promoter homologue (BAD) and Caspase 9;
4) p21-activated protein kinase-2 (PAK-2), which is responsible for
the subsequent activation of both Cdc42 and p38MAPK; and 5) focal ad-
hesion kinase (FAK) and its substrate paxillin [54,55]. In particular,
VEGF utilizes Ca2+ signaling to promote endothelial cell proliferation
and tubulogenesis both in vitro and in vivo [11,56–59]. The pro-
angiogenic Ca2+ response occurs downstream of PLCγ activation and
may adopt distinct patterns depending on the vascular bed of origin.
As widely described elsewhere both by us [11] and by other authors
[1], PLCγ cleaves the phospholipid precursor, phosphatidylinositol 4,5-
bisphosphate (PIP2), into two intracellular secondmessengers, i.e. inosi-
tol 1,4,5-trisphosphate (InsP3) and diacylglycerol (DAG). These two
signaling intermediates activates two distinct modes of [Ca2+]i eleva-
tions in micro- vs. macro-vascular endothelial cells. DAG remains teth-
ered to the plasma membrane to directly gate two members of the
non-selective cation family of canonical TRP channels (TRPC), namely
TRPC3 and TRPC6, in human microvascular endothelial cells [11,25,
60]. TRPC3 and TRPC6, in turn,mediate amonotonic increase in intracel-
lular Ca2+ levels which do not require further Ca2+ release from the en-
dogenous Ca2+ pool. Conversely, in human umbilical vein endothelial
cells (HUVECs), InsP3 rapidly diffuses across peripheral cytosol to
InsP3 receptors (InsP3Rs), which are embedded in the membrane
enveloping the endoplasmic reticulum (ER), the most abundant endo-
thelial Ca2+ reservoir. InsP3Rs function as Ca2+-permeable channels
to release luminally stored Ca2+ upon InsP3 binding, thereby causing a
rapid increase in [Ca2+]i. The consequent emptying of the ER Ca2+
pool signals the opening of store-operated Ca2+ channels (SOCs) in
the plasmamembrane [11,26]. The ensuing inﬂux of Ca2+ shapes a pla-
teau phase of intermediate magnitude between pre-stimulation Ca2+
levels and the InsP3-dependent initial peak that persists as long as
VEGF is presented to the cells [56,57]. Store-operated Ca2+ entry
(SOCE) is a ubiquitous mechanism that, in addition to replenishing the
endogenous Ca2+ pool, delivers the bolus of Ca2+ necessary for the re-
cruitment of a plethora of endothelial Ca2+-sensitive decoders, includ-
ing eNOS, nuclear factor of activated T-cells (NFAT), nuclear factor
kappa-light-chain-enhancer of activated B-cells (NF-κB), activating
protein-1 (AP-1), calpain and myosin light chain kinase (MLCK) [11,
26,61–64]. We have widely illustrated elsewhere the rather heteroge-
neous structure of this pathway in macrovascular endothelial cells [11,
15,20,26]. Brieﬂy, endothelial SOCEmay be initiated by Stromal Interac-
tion Molecule-1 (Stim1), which senses the drop in ER Ca2+ concentra-
tion and rapidly (40–60 s) oligomerizes into clustered puncta that
approach as close as 20–30 nm to the plasma membrane. Herein,
Stim1 binds to and gates two structurally different types of endothelial
SOCs, depending on both the species and the vascular bed. Accordingly,
Stim1 exclusively establishes a physical interaction with Orai1, i.e. the
pore-forming subunit of the Ca2+ release-activated Ca2+ (CRAC) chan-
nel, in HUVECs [56,57]. Conversely, TRPC1 and TRPC4 provide the core
components of plasmalemmal SOCs inmouse aorta [65] and rodent pul-
monary artery [66,67]. In particular, in rat pulmonary artery endothelial
cells (PAECs), the fall in intraluminal Ca2+ induces Stim1 to relocate
into sub-plasmalemmal puncta in a TRPC4-dependent manner, thereby
promoting the association of TRPC4 with TRPC1 [67]. This mechanism
recognizes a privileged role for Orai1, which constitutively interacts
with TRPC4 in un-stimulated cells, increases the probability of TRPC1/
TRPC4 activation by Ca2+ depletion and confers Ca2+-selectivity to
the complex [66].
VEGF is not the only growth factor to utilize Ca2+ signals to exert a
mitogenic effect on mature endothelial cells. Insulin-like growth
factor-1 (IGF-1) and bFGF trigger a massive entry of Ca2+ from the ex-
tracellularmilieu in bovine aortic endothelial cells (BAECs), which is re-
quired for them to proliferate [68,69]. Subsequent studies have led tothe conclusion that arachidonic acid (AA) mediates bFGF-evoked Ca2+
inﬂow by activating TRP Vanilloid 4 (TRPV4) [70]. TRPV4-mediated
Ca2+ inﬂux might promote endothelial proliferation and vascular re-
modeling by enlisting a variety of Ca2+-dependent transcription factors,
such as NFAT, myocyte enhancer factor 2C (MEF2C), Kv channel
interacting protein 3, calsenilin (KCNIP3/CSEN/DREAM), and cytoplas-
mic, calcineurin-dependent 1 (NFATc1) [71,72]. EGF, in turn, elicits cy-
tosolic and nuclear Ca2+ oscillations in rat microvascular endothelial
cells [73], while platelet-derived growth factor (PDGF) evokes irregular
ﬂuctuations of [Ca2+]i in porcine aortic endothelial cells [74]. This spik-
ing response relies on the rhythmic Ca2+ discharge from InsP3Rs and is
maintained by the Stim1-mediated activation of Orai1 [59,73–75].
Unfortunately, the physiological outcome of EGF- and PDFG-induced
intracellular Ca2+ spikes has not been probed in these studies; however,
endothelial cells often use the information encoded in the oscillatory
pattern to ﬁnely tune the Ca2+-sensitive decoders that promote their
pro-angiogenic behavior [76–81]. In addition to mitogens, the chemo-
attractant SDF-1αmay induce endothelialmigration in vitro and recruit
bone marrow-derived HSCs to the target vasculature in vivo through
an increase in [Ca2+]i [12,82]. The signaling pathway downstream of
its G-protein coupled receptor, CXCR4, is still elusive, but it may involve
both InsP3-gated Ca2+ release [12] and store-dependent Ca2+ inﬂow
[82]. Therefore, there is ample evidence in literature to indicate that
VEGF, as well as other growth factors and cytokines, stimulate angio-
genesis by activating a different blend of Ca2+-permeable channels de-
pending on the species and the vascular tree under examination. This
was the background upon which we undertook the examination of
the components of the Ca2+ machinery selected by VEGF in normal
vs. tumor human ECFCs.
3.1. VEGF evokes pro-angiogenic Ca2+ oscillations in normal ECFCs
Among the different subsets of EPCs utilized to induce the angiogen-
ic switch in solid cancers, we focussed on ECFCs, or late outgrowth EPCs,
for fourmain reasons. First, they are the only EPC population possessing
all the features of a true endothelial progenitor and do display any
known hematopoietic marker. Second, unlike CFU-ECs and CACs, they
are capable of forming capillary-like structures in vitro, to originate pat-
ent vessels and to anastomose with host vasculature in vivo [36,37].
Third, they home to sites of malignant growth and physically engraft
within nascent vessels, thereby enhancing tumor size and vasculariza-
tion [40,41]. Fourth, they do require VEGF to proliferate, assembly into
bidimensional tubulary networks, and differentiate into mature endo-
thelial cells [51–53]. Our Ca2+ imaging recordings disclosed that
10 ng/ml VEGF, which is quite close to the dose (25 ng/ml) employed
by Ingram and coworkers to stimulate ECFC expansion in the seminal
study that led to their identiﬁcation [83], triggered asynchronous oscil-
lations in [Ca2+]i in neighboring cells from the same coverslip [13,84].
There were no two cells generating synchronous elevations in [Ca2+]i
in the ECFC monolayer. Such heterogeneity is the hallmark of mito-
gen-induced Ca2+ ﬂuctuations in mature endothelial cells as well as
other non-excitable cell types [73,74,76]. Statistical analysis revealed
the stochastic nature of VEGF-induced intracellular Ca2+ oscillations,
as the standard deviation (SD) of their period was of the same order
as the average value [13,85,86]. We have discussed elsewhere the mo-
lecular underpinnings of the variability in the Ca2+ response to VEGF
in healthy ECFCs [15,26]. Brieﬂy, this diversity, that is retained by umbil-
ical cord blood-derived ECFCs [14], may be engendered by at least two
different sources. First, VEGF binding to VEGFR-2 obeys to a stochastic
regime in vascular endothelium, which is key to determine the angio-
genic phenotype, i.e. proliferative (tip cells) vs. migratory (stalk cell),
adopted by the target cell [43,87]. Second, it is likely that the molecular
nature and the spatial arrangement of Ca2+ release and entry sites dic-
tates the timing of spike generation for each single ECFC [85,86,88]. Nor-
mal ECFCs possess all the three known isotypes of InsP3Rs, namely
InsP3R-1, InsP3R-2, and InsP3R-3, the pattern of expression of their
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are devoid of functional ryanodine receptors [89], whose expression and
biological meaning in mature endothelium have been largely debated
[11]. Additionally, ECFCs are insensitive to H2S stimulation, which elicits
robust Ca2+ signals in normal endothelial cells [60,90,91] and mediates
VEGF-induced Ca2+ entry in breast cancer-derived TECs [60]. VEGF-
induced Ca2+ oscillations were suppressed by U73122, which selectively
blocks PLCγ activity, but not by its inactive analogue, U73343; they were
further hindered by 2-aminoethoxydiphenyl borate (2-APB), which se-
lectively abrogates Ca2+ release from InsP3Rs under our experimental
conditions, i.e. in the absence of Ca2+ in the bathing solution (0Ca2+)
[13]. The Ca2+ transients developed regardless of the absence of extracel-
lular Ca2+, which suggests that they are primarily driven by Ca2+
recycling across the ER membrane; however, they persisted only for a
short time in Ca2+-free saline and resumed only on Ca2+ restitution to
the cells [13]. Therefore, InsP3-dependent Ca2+ release is sufﬁcient to ini-
tiate and support the irregular episodes of intracellular Ca2+mobilization
in ECFCs, but Ca2+ entry across the plasma membrane is necessary to
maintain the oscillations over time. So, which is the membrane pathway
conducting extracellular Ca2+ into these endothelial precursors? Unlike
mature endothelial cells, human circulating ECFCs lack TRPC3 and
TRPC6 [13,14], which mediate VEGF-evoked Ca2+ entry in a DAG-
dependentmanner. Conversely, they express all the putative components
of SOCE, i.e. Stim1–2, Orai1-3, TRPC1 and TRPC4 and exhibit a massive
Ca2+ inﬂux in response to ER Ca2+ store depletion. Therefore, ECFCs
rely on a store-dependent mechanism rather than on a DAG-sensitive
conductance to sustain prolonged intracellular Ca2+ signals. Consistent
with this notion, 1-oleoyl-2-acetyl-sn-glycerol (OAG), a membrane per-
meable analogue of DAG, does not evoke any detectable Ca2+ inrush
[14]. This feature rules out the possibility that TRPC1 forms a second
messenger-operated channel gated by DAG in human ECFCs, as reported
in human prostate cancer cells [92]. Therefore, SOCE provides the molec-
ular gateway for Ca2+ inﬂow in response to agonist stimulation in endo-
thelial precursors [57,89,93]. Parallel work conducted both by us and by
Prof. Beech's lab demonstrated that SOCE is mediated by Stim1, Orai1
and TPC1 in endothelial committed progenitors. RNA interference selec-
tively targeting either Stim1 or Orai1 abolished store-dependent Ca2+ in-
ﬂux in these cells [57,93]. Likewise, SOCE was abrogated by the
expression of a dominant negative mutant Orai1 (R91W), whereas
InsP3-evoked emptying of the ER Ca2+ pool induced eYFP-GFP tagged
Stim1 to cluster into peripheral puncta [57]. Finally, short hairpin RNA-
mediated knockdown of TRPC1 dramatically decreased the magnitude
of store-dependent Ca2+ entry in human ECFCs [93]. These molecular
data are supported by the pharmacological proﬁle of SOCE, that is sensi-
tive to a wide spectrum of rather speciﬁc inhibitors of both Orai1 and
TRPC1 in these cells, including lowmicromolar doses of the trivalent cat-
ions La3+ and Gd3+, 2-APB and YM-58483/BTP2 [20,26]. The question
then arises as to whether these two channel proteins assemble into a
super-molecular ternary complex with Stim1, as illustrated in megakar-
yocytes [94] and mouse submandibular gland cells [95], or constitute
two distinct Ca2+-permeable routes, each recruited by Stim1 [26]. Sup-
pression of either Orai1 or TRPC1 expression reduced SOCE amplitude
to the same extent [93], thereby suggesting that both of them contribute
to the pore forming channel in human ECFCs. Themolecular and pharma-
cological characterization of themost important Ca2+-permeable route in
endothelial committed progenitors enabled us to ascertain its participa-
tion to VEGF signaling. One 1-to-4 Ca2+ transient arose when the cells
were challenged with VEGF in the presence of BTP2, whose effect on
Ca2+ ﬂuctuations thus mimicked the removal of extracellular Ca2+ [13].
In addition, VEGF-evoked Ca2+ inﬂux was nearly absent in normal
ECFCs transfected with a siRNA directed against Stim1 or Orai1 [57],
which is consistent for SOCE requirement to maintain the spiking re-
sponse to VEGF [13]. Thus, the molecular machinery that translates the
extracellular input carried by VEGF into a speciﬁc intracellular output,
i.e. a deﬁned biological response, involves both InsP3Rs and SOCs in nor-
mal ECFCs.VEGF-elicited Ca2+ oscillations drive proliferation and tube formation
in healthy ECFCs. The pro-angiogenic activity of VEGF disappeared when
the cells were pre-treated with BAPTA, a strong membrane-permeable
Ca2+ buffer, or BTP2 to hinder the ensuing elevation in [Ca2+]i [13]. Sim-
ilarly, siRNA-mediated genetic ablation of Orai1 prevented ECFC
tubulogenesis [57]. Therefore, VEGF utilizes intracellular Ca2+ signals to
promote endothelial proliferation and remodeling not only inmature en-
dothelial cells, but also in their progenitors. The Ca2+-sensitive decoder
translating the irregular ﬂuctuations in [Ca2+]i into a biologically mean-
ingful message is represented by NF-κB. The NF-κB signaling system in-
cludes about a dozen different dimmers comprising ﬁve homologous
subunits, i.e. p50, p52, c-Rel, RelA/p65 and RelB [96]. The cytosolic-
nuclear localization of NF-κB is intricately tuned and, in turn, regulates
several key steps of the angiogenic process, including endothelial cell pro-
liferation, survival motility, substrate adhesion, interaction with the
extracellular matrix and capillary morphogenesis [97]. The heterodimer
formed by p65 with p50 or p52 is sequestered in the cytosol by the
association with IκB, an inhibitory protein which masks the nuclear
localisation sequence of the complex. A burst of intracellular Ca2+ oscilla-
tions recruits Ca2+/calmodulin (CaM)-dependent protein kinase IV
(CaMKIV) to activate the enzyme IκB kinase (IKK). IKK, in turn,
hyperphosphorylates IκB on two speciﬁc NH2-terminal serines and tar-
gets the inhibitory protein to site-speciﬁc ubiquitination and eventual
degradation by the proteasome [98]. As a consequence, NF-κB dimers
are released from inhibition and freed into the nucleus, where they turn
on the transcriptional program controlling EPC fate [99,100]. Consistent
with this model, the pharmacological extinction of VEGF-induced Ca2+
oscillations with either BAPTA or BTP2 hindered VEGF-induced IκB phos-
phorylation in normal ECFCs; as expected, the same effectwas exerted by
thymoquinone, which selectively interferes with NF-κB activation [13].
The ﬁnal observation that thymoquinone abrogated ECFC expansion
and tubule formation conﬁrmed that NF-κB serves as the Ca2+-
dependent decoder of VEGF-evoked Ca2+ transients [13]. It has long
been thought that NF-κB stimulation by a spiking signal in endothelial
cells is controlled by the interspike interval (ISI). The transcriptional ac-
tivity of endothelial NF-κB reaches its peak within a frequency range of
Ca2+ spikes ranging from 0–5.2mHz to 1.7–11.7mHz [101]. This proper-
ty does not fully apply to VEGF-challenged ECFCs, which generate irregu-
lar Ca2+ transients. However, resting cells do not exhibit any detectable
elevation in [Ca2+]i, so that the informative content of the irregular
Ca2+ spikes is obvious as compared to silent ECFCs. Recentmathematical
computation has unveiled that any deviation from the pattern of the
Ca2+ spikes in un-stimulated cells conveys a robust (i.e. high signal-to-
noise ratio) message to their downstream effectors, thereby triggering a
biological response [85,88]. The same group has further demonstrated
that the cell-to-cell heterogeneity in the Ca2+ train notwithstanding, sto-
chastic oscillations exhibit a linear correlation between the standard de-
viation of ISI and the average period of the spikes. It turns out that,
under different experimental conditions (e.g. agonist dose, extent of cyto-
solic Ca2+ buffering, cell type), frequency encoding is realized bymoving
up anddown this relation [102]. Interestingly,whenECFCs are exposed to
10 ng/ml VEGF, the interval between two consecutive Ca2+ transients in
most cells ranges between 200 s and 800 s [13], which is adequate to in-
duce the nuclear translocation of NF-κB [101]. Conversely, when VEGF
concentration is raised to 50 ng/ml, the ISI may be lengthened to
1500 s, which is less efﬁcient to stimulate NF-κB. An alternative, albeit
not mutually exclusive, mechanism whereby irregular Ca2+ ﬂuctuations
are decoded involves the spatial distribution of the underlying Ca2+
toolkit. Local Ca2+microdomains may be generated around the cytosolic
mouth of Ca2+-permeable channels to convey information to speciﬁc
Ca2+-sensitive decoders located in their immediate surroundings. The
seminal example has been provided by Parekh's group [103], who dem-
onstrated that leukotriene C4-inducedCa2+ oscillations induced gene ex-
pression and mast cell activation only when they were patterned by
Orai1, while were inefﬁcient if exclusively contributed by InsP3Rs. The
randomness of VEGF-induced Ca2+ spikes in ECFCs might be translated
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InsP3Rs or store-dependent channels (e.g. Orai1 and TRPC1) or both.
These preliminary studies paved theway for the subsequent examination
of the Ca2+ response to VEGF in tumor ECFCs. Once established that
VEGFR-2 is capable of delivering a pro-angiogenic Ca2+ signal to their
normal counterparts, we sough to elucidate whether this pathway was
altered in cancer patients-derived cells and whether it could truly serve
as an optimal target in oncology.
3.2. Rationale for studying the Ca2+ machinery is ECFCs derived from RCC
patients
It has long been established that neoplastic transformation is accom-
panied by a remodeling of the Ca2+ toolkit, which may not be key to
malignant initiation, but contributes to establish some of the ten hall-
marks of cancer [8,9,104], including enhanced proliferation, survival,
angiogenesis and invasion. The derangement of the Ca2+ machinery is
not limited to neoplastic cells, but may also be extended to tumor mi-
croenvironment [105]. Accordingly, TECs harvested from breast carci-
noma up-regulate TRPV4, which governs the remodeling of actin
cytoskeleton that drives endothelial cell migration during the angiogen-
ic switch [70]. Moreover, normal HMECs may be reprogrammed by
adriamycin-resistant human breast cancer cells (MCF-7/ADM) to ex-
press TRPC5, which is otherwise absent in normal cells [106]. Therefore,
we wondered whether tumor ECFCs, which do not belong to the neo-
plastic clone and are isolated from the mononuclear fraction of periph-
eral blood [37], could somehow be inﬂuenced by the malignant
conditions of the donor. The urgency of this studywas further prompted
by the simultaneous investigation of Ca2+ dynamics in ECFCs isolated
from other two sources, i.e. umbilical cord blood (UCB) and peripheral
blood of individuals affected by primary myeloﬁbrosis (PMF). We
found that theCa2+ toolkitmay be assembled according to rather differ-
ent modes in endothelial precursors depending on the superimposed
patho-physiological background. For instance, TRPC3, which is absent
in circulating ECFCs, appears on the plasma membrane of their UCB
counterparts to mediate the inﬂux of Ca2+ that triggers the oscillatory
response to VEGF [13,89]. A more dramatic dysregulation of the Ca2+
machinery occurs in ECFCs derived from PMF patients (PMF-ECFCs),
who suffer from ﬁbrotic bone marrow, splenomegaly, cytopenias, and
multiple disease-related symptoms that reduce quality and length of
life [107]. PMF-ECFCs display a higher ER Ca2+ load, which is associated
to the over-expression of all InsP3R transcripts aswell as of Stim1, Orai1,
Orai3, TRPC1 and TRPC4 proteins [108]. It is, therefore, not surprising
that SOCE magnitude is signiﬁcantly enhanced, albeit two separate
routes may be discriminated based on their pharmacological proﬁle:
one stimulated by passive store depletion and Gd3+-resistant, the
other one recruited by the InsP3-dependent Ca2+ store and Gd3+-
sensitive [108]. A remarkable feature of these cells, that has not been
found in both peripheral blood- and UCB-derived ECFCs [14,89], is
their relative insensitivity to SOCE inhibitors. BTP-2 and La3+ barely af-
fected the proliferation rate, while Gd3+ did not block cell growth [108].
This ﬁnding suggested that VEGF may exploit signaling pathways other
than an increase in [Ca2+]i to control ECFC replication in a pathological
context; in addition, it reawakened the interest towards the earlier
notion that proliferative diseases, such as cancer, may turn off the
requirement for extracellular Ca2+ to drive cell cycle progression
into mitosis [109]. This concept does not rule out the contribution of
Ca2+-permeable channels, which may serve as scaffold proteins to
orchestrate the proliferative process independently on their Ca2+-
conducting properties, as recently shown for Orai1 and Orai3 in some
cell lines, such as HEK293 and HeLa cells [110]. However, it might
have profound therapeutic implications as the in situ disruption of
their encoding genes is far less feasible thanpharmacological abrogation
of Ca2+ ﬂuxes. Therefore, we felt the urgency to examine the remodel-
ing, if any, of Ca2+ signaling in ECFCs isolated from metastatic RCC pa-
tients (RCC-ECFCs). First, RCC is the most common type of kidneycancer in the adults, and several strong evidences hint at EPC participa-
tion to the angiogenic switch in primary tumor [20,29,111–115].
Second, metastatic RCC is the only human cancer where the standard
care for treatment is represented by anti-angiogenic drugs, such as
bevacizumab, sunitinib, and sorafenib [20,116]. As described in a previ-
ous paragraph, however, clinical practice revealed that a fraction of the
patients are intrinsically refractory towards this treatment, while those
who undergo an initial remission display a later tumor relapse and
ultimately die [20,116]. However, TECs cultured from human RCC do
respond to VEGF stimulation, which renders them sensitive to
bevacizumab, sunitinib and sorafenib [117]. It turns out that an addi-
tional component of tumor vasculature must be refractory to this
growth factor [20]. All the studies described above concurred to demon-
strate that EPCs require a functional VEGFR-2 to sustain the malignant
transformation, but they drew this conclusion by exploiting normal,
rather than tumor, cells. Third, RCC has recently been associated to an
important derangement of Ca2+ machinery, Orai1 and TRPC6 expres-
sion being enhanced in primary tumor samples as compared to normal
renal tissues [118,119]. Conversely, TRPC4 is down-regulated in two
different human kidney carcinoma cell lines [120]. These alterations
may play a central role in the neoplastic transformation of normal kid-
ney. While TRPC6 up-regulation favors the transition through G2/M
phase [118], and Orai1 regulates RCC cell proliferation and migration
[119], the loss of TRPC4 leads to a diminished secretion of the endoge-
nous inhibitor thrombospondin-1, thereby promoting the angiogenic
switch [120]. Thus, understanding whether RCC-ECFCs develop Ca2+-
handling abnormalities might permit the accomplishment of two
goals. It could unveil alterations in the pro-angiogenic signaling path-
ways initiated by VEGF, thereby providing a solid cellular andmolecular
rationale for the failure of anti-VEGF therapies; and, at the same time, it
could highlight unforeseen targets, i.e. Ca2+-permeable ion channels
and/or Ca2+ transporters, to devise alternative treatments.
3.3. The Ca2+ machinery is deranged in tumor ECFCs: consequences for
VEGF-induced Ca2+ oscillations
Our work was carried out on ECFCs isolated from naïve metastatic
RCC patients, i.e. these individuals were newly diagnosed and yet to un-
dergo the anti-angiogenic treatment. There was no difference in the
basal Ca2+ concentration, as measured by the resting Fura-2 ratio, be-
tween control and RCC cells; in addition, there was no unsolicited
Ca2+ activity in tumor ECFCs [93], while spontaneous oscillations in
[Ca2+]i arise in murine carcinoma stem cells [121,122]. Nevertheless,
ER Ca2+ load is signiﬁcantly reduced in RCC-ECFCs, as conﬁrmed by a
variety of experimental approaches. First, we measured the magnitude
of cytosolic Ca2+ mobilization consequent to SERCA inhibition in the
absence of extracellular Ca2+, which is an established procedure to
evaluate intraluminal Ca2+ levels (Fig. 3A–B). Second, we transfected
the cells with a plasmid encoding the Ca2+-sensitive luminescent
protein aequorin speciﬁcally targeted to the mitochondrial matrix,
which faithfully senses InsP3-dependent Ca2+ discharge. Consistent
with the previous data, InsP3 triggers a lower increase in cytosolic
(Fig. 3C–D) and intra-mitochondrial (Fig. 3G–H) Ca2+ concentration
in RCC-ECFCs as related to normal cells, thereby conﬁrming that ER
Ca2+ dynamics are altered in the former [93]. This feature may help to
disclose the potential impact of ECFCs on tumor vasculature. It is well
known that a reduction in intraluminal Ca2+ levels favors cancer cell
survival and evasion of programmed cell death [123,124]. Chronic
underﬁlling of the ER and, consequently, of mitochondrial Ca2+ levels
reduce the execution of the intrinsic apoptosis pathway [123,124],
that culminates in the opening of permeability transition pore (PTP)
and permits release crucial components of the apoptosome, including
cytochrome c, apoptosis-inducing factor, and SMAC/DIABLO [125].
Moreover, this fall in ER Ca2+ has been associated to the over-
expression of P-glycoprotein (P-gp), a ABCB1member of ABC transport-
er family that drives the efﬂux of many chemotherapeutic agents out of
Fig. 3. Remodeling of the Ca2+ toolkit in endothelial progenitor cells isolated from patients suffering from renal cellular carcinoma (RCC-EPCs). Both normal EPCs (N-EPCs) and RCC-de-
rived cells with loadedwith the Ca2+ sensitive dye, Fura-2/AM (4 μM), and subsequently exposed to the “Ca2+ add-back” protocol to monitor both ER Ca2+ levels and SOCE. Stimulating
the cells with either cyclopiazonic acid (CPA; 10 μM) (A–B) or the InsP3-producing autacoid, ATP (100 μM) (C–D), revealed that RCC-EPCs display a reduction in intraluminal Ca2+ and
higher SOCE as compared to N-EPCs. Likewise, when the cells were transfected with plasma membrane-targeted aequorin, the magnitude of CPA-induced Ca2+ inﬂow was signiﬁcantly
larger in RCC-EPCs (E–F). Finally, when EPCs were transfected with mitochondrial-targeted aequorin, CPA-induced changes in intra-mitochondrial Ca2+ concentration ([Ca2+]mito)
reﬂected those recorded in Fura-2/AM-loaded cells (G–H). In Panels B, D, F, H, the asterisk indicates p b 0.05 and the data displayed are the average±SEof pooled data. The EPC population
utilized in these sets of experiments belongs to the ECFC subtype.
Extracted from [93].
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the nuclear translocation of the human telomerase reverse transcriptase
(hTERT), which functions as catalytic component of telomerase, therebyadversing telomeric shortening and cellular senescence in A549
human lung adenocarcinoma cells [127]. The interaction between en-
dogenously liberated Ca2+ and hTERT is likely to be mediated by the
Fig. 4. VEGF does not elicit any detectable increase in [Ca2+]i in endothelial progenitor
cells isolated from patients suffering from renal cellular carcinoma (RCC-EPCs). VEGF
(10 ng/ml) triggers intracellular Ca2+ oscillations in N- but not RCC-EPCs. The black trac-
ing is representative of the Ca2+ spikes elicited by VEGF in N-EPCs, while the gray tracing
refers to RCC-EPCs, which are insensitive VEGF and do not display any detectable increase
in [Ca2+]i uponVEGF stimulation. The EPC population utilized in these sets of experiments
belongs to the ECFC subtype.
Extracted from [93].
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Prof.Prevarskaya's laboratory has shown that the drop in the intracellular
Ca2+ pool is caused by a reduction in both Sarco-Endoplasmic Reticulum
Ca2+-ATPase (SERCA) 2B and calreticulin levels in neuroendocrine-
differentiated prostate cancer cells [124]. While SERCA pumps are the
only mechanism responsible for Ca2+ sequestering into ER lumen,
calreticulin, as well as calnexin, glucose-related protein (GRP)-78, and
GRP-94, are Ca2+ binding chaperones that maintain ER Ca2+ levels [11].
These ﬁndings have subsequently been conﬁrmed in small and non-
small cell lung cancer cell lines [129]. Our unpublished observations indi-
cate that there is no difference in the expression of SERCA2B, calreticulin
and calnexin betweenRCC-ECFCs and their healthy counterparts. Howev-
er, the rate of [Ca2+]i recovery to the baseline is signiﬁcantly slower in
RCC-ECFCs stimulated with ATP as compared to control cells [93]. Under
these conditions, all Ca2+-removing systems, i.e. mitochondria, SERCA,
plasma membrane Na+/Ca2+ exchanger (NCX) and plasma membrane
Ca2+-ATPase (PMCA), are active andmay clear cytosolic Ca2+. Converse-
ly, the decay to resting levels is unaltered when the [Ca2+]i is elevated by
CPA, i.e. when SERCA is inhibited and Ca2+ is mainly extruded across the
plasma membrane by both PMCA and NCX. These data strongly suggests
that the delayed removal of cytosolic Ca2+ observed in the presence of
ATP, but not CPA, is due to the impairment of SERCA activity [130]. This
feature might nicely explain the reduced intracellular Ca2+ reservoir in
RCC-ECFCs, albeit it remains to be experimentally probed. Moreover, fu-
ture studies will have to ascertain whether Bax Inhibitor-1 (BX-1), a
proto-oncogene that controls ER Ca2+ permeability, is up-regulated in
RCC-ECFCs, thus lowering steady-state intraluminal Ca2+ levels [131].
Supporting the evidence that these cells are less prone to release endoge-
nous Ca2+ is the down-regulation of InsP3R2 and InsP3R3 transcripts,
while InsP3R1 is not even present [93]. This ﬁnding is somehow in con-
trast with the notion that InsP3Rs are generally more abundant in malig-
nant cells [8,131], but we should recall that ECFCs do not derive from
neoplastic clones and that InsP3R1 expression is repressed in a colorectal
cancer cell line [132]. The reduction in ER Ca2+ content associated to the
loss of all InsP3R isoforms might be an adaptive mechanism devised by
tumor ECFCs to dismantle pro-death and stimulate pro-survival decisions
in tumor stroma [133]. This might dramatically increase the probability
that RCC-ECFCs successfully home to and are retained within the hostile
microenvironment of the growing neoplasm, thereby favoring the angio-
genic switch. Consistently, our preliminary data revealed that RCC-ECFCs
aremore resistant to serumstarvation- and rapamycin-induced apoptosis
as compared to normal cells (Poletto, Rosti and Moccia, unpublished
observations).
While RCC-ECFCs liberates less Ca2+ in response to InsP3-dependent
store depletion, they undergo a dramatic up-regulation of SOCE
(Fig. 3A–H) due to the higher expression of Stim1, Orai1, and TRPC1
[93]. Both the pharmacological proﬁle and the molecular make-up of
SOCs are not different as compared to control cells, and this feature en-
abled us to assess whether and how they impact on the angiogenic ac-
tivity of RCC-ECFCs. The inhibition of SOCE with BTP2 and low
micromolar doses of lanthanides suppressed both cell proliferation
and tube formation when these cells were seeded in the presence of
EGM-2, an endothelial growth medium enriched with VEGF, bFGF,
insulin-like growth factor (IGF) and EGF [93]. Thus, RCC-ECFCs differ
from PMF-ECFCs, which replicate quite well despite for the blockade
of InsP3-dependent SOCs [108]. No study has hitherto analyzed the ex-
pression and the role, if any, of Stim1, Orai1 and/or TRPC1 in TECs,
while it is nowestablished that these proteins are grossly altered in neo-
plastic cells [134–136]. In this perspective, it is intriguing that Stim2 and
Orai3 levels are not changed in RCC-ECFCs [93], while they are dysregu-
lated in both PMF-ECFCs [108] and several cancer types [137,138]. The
largermagnitudeof SOCE in RCC-ECFCs correlateswith the higher abun-
dance of circulating EPCs in RCC patients. There is nopublished informa-
tion yet about RCC-ECFC frequency in peripheral blood of these
individuals, but it is conceivable that they are signiﬁcantlymore numer-
ous than in healthy individuals. One explanation is likely to be providedby their higher resistance to apoptosis, an intrinsic property that may
enhance their levels in circulation as well as within the tumor. But
does the up-regulation of Stim1, Orai1 and TRPC1 has the potential to
favor RCC-ECFC proliferation within the bonemarrow, egression in sys-
temic vasculature and engraftment within the tumor? As anticipated in
a previous paragraph, it has long been thought that latent micro-
metastases stimulate and recruit circulating EPCs through the over-
production of growth factors and cytokines, such as VEGF and SDF-1α.
VEGF is a major component of the commercial EGM-2medium routine-
ly employed to elicit ECFC expansion and tubulogenesis. Consequently,
we turned to monitor VEGF-induced Ca2+ oscillations in RCC-ECFCs by
expecting an aberrant and spectacular increase in their amplitude, fre-
quency and/or duration. Surprisingly,we found that VEGF does not elicit
any detectable increase in [Ca2+]i in these cells, despite the fact that the
same batch and dose of agonist trigger beautiful Ca2+ spikes in control
ECFCs (Fig. 4) [93]. Enhancing VEGF concentration up to 100 ng/ml did
not render RCC-ECFCs more sensitive and not even a single transient
arose (unpublished observations from our lab). Thus, VEGF does not
elicit pro-angiogenic Ca2+ oscillations in RCC-ECFCs, albeit they express
normal levels of VEGFR-2 [93]. NF-κB transcriptional activity may, how-
ever, be recruited by signaling pathways other than Ca2+, such as pro-
tein kinase C (PKC), mitogen-activated protein kinases (MAPK)/
extracellular signal-regulated kinases (ERK), phosphatidylinositol 3-
kinase (PI3K)/protein kinase B (Akt), glycogen synthase kinase-3β
(GSK3β) and casein kinase II (CKII) [139,140]. Nevertheless, our prelim-
inary data disclosed that VEGF-induced, NF-κB-mediated gene expres-
sion (VCAM-1, ICAM-1, E-selectin) is robust in healthy endothelial
precursors, but is absent in RCC-ECFCs (Poletto, Rosti, and Moccia,
unpublished data). These data strongly suggests that VEGFR-2 does
not properly function in these cells: this featuremightwell be explained
by the ER Ca2+ underﬁlling and/or the down-regulation of InsP3Rs
described above. The ER is not a homogenous organelle, but it exhibits
tremendous plasticity and heterogeneity in the distribution of its
Ca2+-handling/transporting proteins [141]. The intricate tubular net-
work of the ER is organized into modular Ca2+ signaling units, which
operate independently or in synchrony, thus generating either local or
global Ca2+ elevations [141]. The reduction in luminal Ca2+ levels
might be stronger in the ER sub-compartment supporting the InsP3-
evoked Ca2+ response to VEGF that gives raise to the oscillations, thus
preventing the onset of the pro-angiogenic signal. Similarly, InsP3 syn-
thesized upon VEGFR-2 activation might fail to bind to its target recep-
tors, as they are deﬁcient in RCC-ECFCs, and, consequently, to trigger the
spiking activity. Future work is mandatory to conﬁrm that VEGFR-2
does not stimulate RCC-ECFCs. Moreover, it will be necessary to
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dergo auto-phosphorylation in these cells. Indeed, the blockade of
VEGFR-2 signaling by the preferential expression of amodulatory/ancil-
lary protein in either RCC-ECFCs or neighboring stromal cells should not
be ruled out. For instance, VEGFR-1 has long been known to trap VEGF
with higher afﬁnity thanVEGFR-2, thereby serving as negative regulator
of angiogenesis [55]. Moreover, the expression of delta-like ligand 4
(DLL4) in human glioblastoma cells activates Notch signaling in adja-
cent TECs, thereby down-regulating VEGFR-2 expression and inducing
tumor resistance to bevacizumab [142].
This ﬁnding might have remarkable pathological and therapeutic
implications. According to the data generated by RCC-ECFCs, targeting
VEGFmight not be sufﬁcient to block EPCmobilization in neoplastic pa-
tients. These cells are indispensable for inducing the angiogenic switch
in solid malignancies. However, if they display a silent VEGFR-2, either
humanized anti-VEGF monoclonal antibodies (bevacizumab) or tyro-
sine kinase inhibitors (sunitinib and sorafenib) will not prevent them
from homing to and integrating within tumor vessels. This is why
tumor ECFCs are not able to sense VEGF. This feature could shed light
on the refractoriness of human kidney cancer to current therapies. In-
deed, TECs are certainly sensitive to anti-VEGF drugs, as shown by
their sensitivity to bevacizumab, sunitinib and sorafenib [117].We spec-
ulate that, in real patients and not in xenograftedmurinemodels, tumor
endotheliummight initially stop proliferating and undergo apoptosis in
response to the anti-angiogenic treatment. However, subsequent tumor
hypoxia will stimulate the bonemarrow to release EPCs, which home to
the shrinked vasculature, and proliferate and restore blood supply in
spite of anti-VEGF inhibitors. Several issues remain to be addressed.
First, are the other EPC subsets, i.e. CFU-ECs and CACs, equally insensi-
tive to VEGF in subjects affected by RCC? Second, does this paradigm
apply to other cancer types? It will be important to assess whether the
Ca2+ toolkit and VEGFR-2 signaling are dys-regulated in other malig-
nancies. Third, which is the physiological inducer of SOCE in RCC-
ECFCs? The answer to this question is likely to unveil the ideal target
for anti-angiogenesis therapy in RCC patients. Accordingly, SOCE is
operative and sustains RCC-ECFC proliferation and tubulogenesis in
the presence of EGM-2; this medium is enriched with growth factors
other than VEGF, such as bFGF and EGF, which all trigger pro-
angiogenic Ca2+ signals in mature endothelial cells. Thus, another li-
gand is responsible for SOCE activation in RCC-ECFCs: uncovering its
(their) identity(ies) is predicted to reveal the mitogen(s) responsible
for their mobilization in vivo and to suggest alternative therapeutic
treatments. In this view, growing attention has been paid to bFGF,
whose plasma levels exhibits a dramatic increase before the metastatic
progression in RCC patients [20]. Consistently, several pharmacological
companies are developing an original approach to target bFGF signaling
by exploiting either anti-bFGF or anti-bFGF receptor agents, albeit they
are still far from entering the clinical practice [49]. The combination be-
tween VEGF and bFGF inhibition might, therefore, overcome patient re-
fractoriness to anti-angiogenic treatment. However, the ﬁnding that
Orai1- and TRPC1-mediated Ca2+ inﬂow is central to RCC-ECFC activa-
tion sheds light on an additional target for human kidney cancer treat-
ment that has the advantage to circumvent the limitation imposed by
drug resistance.
3.4. Orai1 and TRPC1 as alternative targets to prevent EPC activation and
tumor growth
A growing body of evidence has been accumulated to substantiate
the proposal that SOCE may be successfully inhibited to adverse tumor
growth and metastatization [9,20,25,134]. For instance, Stim1- and
Orai1-mediated Ca2+ inﬂow drives cell cycle progression and metasta-
tic behavior inmany human cancers, including those of breast and uter-
ine cervix [59], glia [136], lungs [143], colon [144], nasopharyngeal and
esophageal tracts [145,146], and epidermis [138]; likewise, TRPC1 is
implicated in proliferation and motility of a widespread number ofneoplastic cells, such as those of human breast carcinoma [147,148],
glioblastoma multiforme [149], non-small lung cell carcinoma [150,
151], nasopharyngeal carcinoma [152], and ovarian carcinoma [153].
The observation that these proteins are frequently over-expressed in
cancer cells is a strong indicator of the central role they serve during
neoplastic transformation [8]. Therefore, targeting store-dependent
Ca2+ inﬂux might reliably induce tumor regression and eradicate dis-
seminated metastases in human patients [8,9,20,25,134], as suggested
by pre-clinical studies on xenografted animals [59,146,154,155]. We
speculate that SOCE constitutes an intriguing target to develop alterna-
tive anti-angiogenic treatments of RCC as well as of other highly
vascularized solid malignancies. Unlike VEGFR-2, Orai1 and TRPC1 do
sustain human RCC-ECFC growth and tube formation in vitro and
there is no reason to believe it should be different in real patients. More-
over, this route is gated following the InsP3-evoked depletion of endog-
enous Ca2+ reserves, thus representing the putative endpoint of the
myriad of pro-angiogenic pathways activated during RCC development
[20]. As mentioned above, the metastatic transition of human kidney
cancer is preceded by a cytokine storm released in peripheral circula-
tion: serum levels of bFGF, HGF and interleukin-6 (IL-6) are signiﬁcantly
higher as compared to healthy individuals [156]. In particular, bFGF and
HGF are virtually capable of activating PLCγ to catalyze InsP3 synthesis,
which might ultimately lead to SOCE opening. Consistent with this hy-
pothesis, HGF-induced CFU-EC proliferation and migration are partly
regulated by Stim1 and TRPC1, as discussed in [12] and [26]. Conse-
quently, the pharmacological blockage of SOCE in mRCC patients pro-
vides one hitherto unmet therapeutic advantage: with one single shot
(i.e. a speciﬁc inhibitor of Ca2+ entry), it affects the signaling mecha-
nism onto which all the growth factors and cytokines responsible for
tumor resistance and escape from the therapy converge [20]. In addi-
tion, SOCE underlies the activation of bonemarrow-derived hematopoi-
etic cells that support EPCs during tumor vascularization (see references
in [12] and [20]), such as CD45+/CD11 myeloid cells, dendritic cells,
mast cells, and neutrophils. When considering the impact of SOCE on
healthy endothelial cells [11,56,57], this pathway is likely to stimulate
TECs as well. Conversely, TRPV4, which controls the early steps of
TEC-dependent angiogenesis [25,70], does not activate ECFCs at least
when isolated from healthy donors [157]. Finally, it has recently been
shown that Stim1 and Orai1 constitute a native pathway that is critical
for RCC cell proliferation and migration [119]. Therefore, targeting
SOCE is envisaged to affect all the cellular components of tumor micro-
environment even without any adjuvant (e.g. chemo-, immuno-, or
radio-therapy) administration [20]. Once again, a number of cumber-
some roadblocks separate this hypothesis from its pre-clinical testing.
First, we have to examine the efﬁcacy of SOCE inhibitors on hematopoi-
etic progenitors isolated fromRCC patients. As evident from the discrep-
ancies between animal models and oncologic reality, cells derived from
healthy subjects do not truly reﬂect the biology of theirmalignant coun-
terparts. Second, selective non-small molecule blockers of Orai1 and
TRPC1 are yet to be commercially available. The unspeciﬁc action
exerted by 2-APB on membrane conductances other than Orai1 and
TRPC1 has widely been illustrated [24,26]. BTP2, in turn, is a selective
SOCE antagonist in ECFCs [26,93], but not in lymphocytes [158]. Synta
Pharmaceuticals has recently synthesized Synta 66 (3-ﬂuoropyridine-
4-carboxylic acid (2′,5′-dimethoxybiphenyl-4-yl)amide) (WO 2005/
009954), which hinders Orai1-mediated Ca2+ inﬂow with no reported
action on TRPC or TRPV channels [57,159]. Similarly, the novel pyrazole
derivative Pyr6 has been designed to discriminate between Orai1- and
TRPC3-mediated Ca2+ inﬂow [160]. However, the characterization of
these intriguing compounds is at an early stage and they have not
been probed on xenograftmodels of human cancers yet.Moreover, a re-
cent study showed that Stim1-dependent Ca2+ inﬂow controls antitu-
mor immunity by CD8+ T cells and is essential to adverse the
engraftment of melanoma and colon carcinoma cells [161]. It turns out
that targeting SOCE might favor, rather than contrast, the inﬁltration
and spreading of tumor cells. Nevertheless, blocking Orai1 repressed
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therapy-resistant inducible T regulatory cells (iTreg) [162], which pro-
mote tumor progression by down-regulating effector T cells [163]. Eval-
uating the consequences of Orai1 and TRPC1 inhibition on the immune
response against cancer development is, therefore, mandatory before
introducing this approach into a pre-clinical setting. It is, however, sug-
gestive that blocking SOCE did not cause any evident untoward effects
in two different models of human cancer xenografts [146,154]. Chen
and coworkers ﬁrst investigated the impact of SK&F96365, a non selec-
tive SOCE inhibitor, on 4T1 mouse mammary tumor cells metastatiza-
tion in BALB/c mice. Twenty days after their implantation in the
mammary gland, SK&F96365 repressed the dissemination of metastatic
lesions to the lungs “with no signs of overt toxicity” on the animals,
which well tolerated the treatment [154]. More recently, Zhu et al.
assessed the effect of SK&F96365 on NCr nu/nu nude mice subcutane-
ously inoculated with KYSE-150 cells, a malignant esophageal squa-
mous cell carcinoma (ESCC) cell line. The application of this drug for
up to two weeks signiﬁcantly retarded tumor growth and “appeared
to be safe” for the animals “since no obvious abnormality … was ob-
served” [146]. Finally, we have recently demonstrated that the pharma-
cological inhibition of SOCE in metastatic RCC cells isolated from
patients resistant to anti-angiogenic treatments does not dampen cell
proliferation [164]. This feature, which could be ascribed to patient's re-
action to the therapy, suggests that future studies should be conducted
in vivo to assess whether anti-VEGF drugs impact on subject sensitivity
to SOC blockers.
3.5. A few hypotheses to comprehend the derangement of the Ca2+machin-
ery in tumor ECFCs
The derangement of the Ca2+ toolkit in RCC-ECFCs does not only
provide one of the ﬁrst mechanistic explanations of the failure of anti-
VEGF therapies. It sheds new light on themolecularmechanisms under-
pinning neoplastic transformation. Somatic and germline variants in
lung cancer and germline mutations in colon cancer of ATP2A2 gene
(encoding for SERCA2) have been reported [165], while germlinemuta-
tions of the ATP2A2 and ATP2A3 (encoding for SERCA3) genes might
serve as susceptibility alleles in head and neck squamous cell carcinoma
[166,167]. However, it is generally accepted that the remodeling of Ca2+
transport proteins in cancer cells is associated to either epigenetic
changes or post-translational modiﬁcations in the properties of pre-
existing signaling components [8,104]. As aforementioned, ECFCs un-
dergo distinct alterations of the Ca2+ toolkit depending on the patho-
physiological background of the donor [14,93,108]; this feature hints
at tumor microenvironment as a key instigator of the changes in intra-
cellular Ca2+ homeostasis. Cancer is an ecosystem operating inside liv-
ing organisms and comprising not only transformed cells, but also their
neighboring partners, includingﬁbroblasts, adipocytes, endothelial cells
and bone marrow-derived hematopoietic and endothelial precursors
[27,168]. Cancer cells utilize multiple autocrine and paracrine signaling
pathways to coordinate a sophisticated network of interactions with
stromal cells. This molecular cross-talk reprograms tumor associated-
host cells to facilitate and sustain disease progression and metastases,
at the same time protecting the malignant milieu against aggressive
pharmacologic and radiotherapeutic interventions [27,168]. Among
the mechanisms of phenotypic heterogeneity mentioned above, endo-
thelial cells might undergo epigenetic modiﬁcations induced by the
transfer of both bioactive factors (membrane receptors and channels,
protein and lipids) and genetic information (oncogenes, mRNAs, and
miRNAs) or through apoptotic bodies and/or exosomes detached from
cancer cells [106,169–175]. The consequent reprogramming of the tran-
scriptional activity hijack normal endothelial functions to facilitate the
angiogenic switch, thereby favoring tumor growth andmetastatization.
For instance, renal cancer stem cells liberate microvesicles (MVs) con-
taining mRNAs and miRNAs that confer an activated phenotype to
normal endothelial cells, stimulating their proliferation and vesselformation after in vivo inoculation in non-obese diabetic severe com-
bined immunodeﬁciency (NOD/SCID) mice [170]. Moreover, tumor-
conditioned endothelial cells silence angiogenesis-suppressing genes
in association with promoter histonemodiﬁcations, but not DNAmeth-
ylation [173], which invokes the key role of histone deacetylase (HDAC)
in the epigenetic regulation of tumor angiogenesis. From the point of
view of Ca2+ signaling, the co-culture of bone marrow-derived human
mesenchymal stem cells (MSCs) with several epithelial cancer lines
caused a reduction in basal Ca2+ inﬂux in MSCs that was coupled with
an increased expression of hematopoietic makers [176]. Furthermore,
MCF-7/ADM cells are capable of transferring TRPC5 to HMECs, thereby
providing them with the source of Ca2+ necessary to activate NFAT
and induce P-gp expression [106]. This chain of events underlies the ac-
quired resistance of HMECs to the chemotherapeutic agent adriamycin
both in vitro [106] and in vivo [177]. Consistently, TRPC5-containing ex-
tracellular vesicles are far more abundant in peripheral blood from
breast cancer patients who underwent chemotherapy, but did not
show complete regression, as compared to naïve ones [178]. This
novel mode of communication between tumor and resident endothelial
cells might lead to TRPV4 up-regulation in B-TECs as well [70]. It is now
evident that a malignancy does not only inﬂuence the immediate sur-
roundings of the primary tumor compartment: it exerts long-range sys-
temic effects by releasing soluble factors and exosomes in circulation
that reach the bone marrow and, herein, educate hematopoietic pro-
genitor cells to support tumor growth and dissemination [179,180].
This paradigm also applies to EPCs that may be reprogrammed by neo-
plastic cells to over-express miR-10b and miR-196b, which sustain
angiogenesis-mediated LLC growth in xenografted animals [34]. There-
fore, we speculate that the components of the Ca2+ toolkit are plastical-
ly selected and shufﬂed by ECFCs depending on the instructive signals
emanating from cancer cells. This hypothesis is supported by the obser-
vation that ECFCs isolated from PMF and RCC patients exhibit clearly
distinct Ca2+ signatures in terms of InsP3R, Stim, Orai and TRPC expres-
sion [93,108]. Likewise, our preliminary data reveal that ECFCs harvest-
ed from naïvemammary carcinoma patients further differ fromnormal,
PMF- and RCC-ECFCs (manuscript in preparation from our group). Just
like TECs retain their original site-speciﬁc epigenetic ﬁngerprint, endo-
thelial precursors might differentially be conditioned by tumor-
derived moieties that are peculiar for each malignancy [179,180]. The
elucidation of the signals by which growing tumors reprogram the
Ca2+ toolkit of bone marrow-derived ECFCs will not only shed more
light on the complex biology of neoplastic transformation: it will likely
emerge as a new avenue of research in the endless quest for novel
anti-angiogenic strategies.
4. Conclusions
The investigation of the intracellular Ca2+ dynamics in tumor ECFCs
has been instigated by the curiosity to challenge the hypothesis that
tumormicroenvironmentmay condition the host organism event at re-
mote distances from the primary lesion site. Our initial results that are
corroborated by the subsequent ﬁndings obtained on different models
of proliferative diseases, support the notion that ECFCs, which are part
of the non-hematopoietic EPCs, undergo a dramatic remodeling of
their Ca2+ machinery. Thus, the dys-regulation of Ca2+ handling/
transporting proteins that has long been reported in neoplastic cells
has now to be extended to tumor microenvironment, which is consis-
tent with the data provided by tumor and tumor-conditioned endothe-
lial cells [70,106]. It will be mandatory to conﬁrm whether the Ca2+
signature of circulating ECFCs is typical of a given malignancy or not.
Novel ﬂow cytometry-based assays are currently under development
to accelerate the expansion of ECFC clones from peripheral blood;
when these assays will be available, it might be possible to utilize the
pattern of InsP3Rs, Stim, Orai or TRPC protein expression as a prognostic
marker of a speciﬁc cancer type. The road ahead is still long towalk: ad-
ditionally, it will be necessary to ﬁnd the correlations, if any, between
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Needless to say, we will have to evaluate also whether and how all the
other components of the Ca2+ machinery (e.g. SERCA, PMCA, NCX,
TRPV and TRPM) vary in tumor ECFCs. The therapeutic implications of
the alterations in intracellular Ca2+ homeostasis were rather unexpect-
ed. The failure of VEGF to trigger the oscillatory signal and its down-
stream transcriptional response in RCC-ECFCs might aid to understand-
ing the well known inefﬁcacy of anti-angiogenic drugs in kidney cancer
patients. This treatment does not prove to be as efﬁcient as in pre-
clinicalmodels also in other life-threatening cancer types, such asmam-
mary carcinoma. As recognized by several authors, anti-VEGF therapy
has been devised by utilizing normal endothelial cell lines, such as
HUVECs and HMECs, rather than tumor-conditioned or patients-
derived cells. The availability of modern technologies to harvest endo-
thelial cells from human tumor vasculature and truly endothelial pro-
genitors from peripheral circulation of neoplastic subjects is predicted
to amend this therapeutically relevant mistake. Albeit the drop in ER
Ca2+ levels might be responsible for VEGF failure, and therefore for pa-
tient resistance to anti-VEGF inhibitors, Ca2+ signaling offers a novel
battery of promising, and easily accessible from the blood stream, tar-
gets. Stim1, Orai1 and TRPC1 control cell proliferation not only in
ECFCs but also in the other cellular components of tumormicroenviron-
ment, including resident endothelial cells, ﬁbroblasts, bone marrow-
derived hematopoietic progenitors and cancer cells. It will be indispens-
able to ascertain whether this ubiquitous mechanism of Ca2+ entry is
also operative in stromal cells to enable one single bullet (i.e. a speciﬁc
SOCE inhibitor) to target all the cellular actors of human malignancies
and circumvent refractory mechanisms.Acknowledgements
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